Does Mounjaro cause yeast infections?
The current U.S. Mounjaro prescribing information does not list yeast or genital fungal infection among its common adverse reactions, and it does not give the 3.2% rate or week-by-week pattern previously stated here. The sources reviewed do not establish that rapid glucose reduction causes a temporary Candida rebound. The earlier mechanism and risk timeline were unsupported and have been removed.
That does not prove an individual infection cannot occur during treatment. Timing alone cannot establish its cause. The relevant comparison is tirzepatide adverse-event evidence, not findings for another drug class.
What the current label reports
The current DailyMed Mounjaro label lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain as adverse reactions reported in at least 5% of treated patients. It does not provide a Candida-specific incidence table. The label cannot support the former dose-specific percentages, number needed to harm, or claim of a first-16-week cluster.
Evidence summary
| Question | What the current source establishes |
|---|---|
| Does the label list yeast infection as a common adverse reaction? | No, it is not in the common-reaction list. |
| Does the label report a 3.2% rate versus 1.1% placebo? | No such figure appears in the label reviewed. |
| Does evidence show a Candida rebound from glucose normalization? | The cited sources do not establish that mechanism or a 4-to-12-week window. |
| Can an infection occur while taking Mounjaro? | Timing alone cannot establish or rule out an individual cause. |
Primary source
Current DailyMed U.S. prescribing information for Mounjaro.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Mounjaro is a registered trademark of Eli Lilly and Company. Monistat, Gyne-Lotrimin, and Vagistat are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →